Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,564.70
22.70 (1.43%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹90.88K Cr
MID CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
26.1
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,016.1+54.0%
52W High₹1,636.8-4.4%
Current Price
₹1,564.70
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,251.76
Upper Circuit₹1,877.64
Reference Price
₹1,564.70
Investment Checklist
Rounding Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1605.8
Double Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1601.7
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Volume divergence: Bearish (price up, volume down)
EMA(9) Crossover: Price crossed below EMA(9): Fresh bearish weakness signal.
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
50%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1539.23
EMA50
1485.23
EMA200
1313.99
Price Action
MIXED
NEUTRAL
Higher Highs3
Higher Lows4
Lower Highs6
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹1636.80
Support (Below)
₹1550.00
₹1496.50
₹1459.50
₹1411.00
₹1391.00
Volume Analysis
TrendSTABLE
Change-4.30%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹1549.05
3% Risk₹1517.76
5% Risk₹1486.46
7% Risk (Custom)
₹1455.17Technical Levels
1x ATR (Volatility)₹1523.13
2x ATR (Swing)₹1481.56
3x ATR (Trend)₹1439.99
Immediate Support₹1550.00
Moving Averages
EMA 20 (Medium-term)₹1539.23
EMA 50 (Trend)₹1485.23
EMA 200 (Long-term)₹1313.99
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹7,893.2 Cr | ₹8,381.1 Cr | ₹7,791.8 Cr | ₹8,604.5 Cr |
| Net Profit | ₹845.8 Cr | ₹903.5 Cr | ₹824.8 Cr | ₹910.3 Cr |
| EPS | ₹14.56 | — | ₹14.20 | ₹15.67 |
| Operating Profit | ₹1,736.9 Cr | ₹1,819.5 Cr | ₹1,710.3 Cr | ₹1,896 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Biocon Limited | ₹418.50 | +3.70% | 177.4 | ₹67.83K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 17 Apr 2026 | Buy Back | BUYBACK |
| 08 Aug 2025 | Interim Dividend - Rs 4 Per Share | INTERIM_DIVIDEND |
| 26 Aug 2024 | Annual General Meeting | AGM |
| 30 Jul 2024 | Buy Back | BUYBACK |
| 20 Feb 2024 | Interim Dividend - Rs 1.50 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for AUROPHARMA
View AllNEWS
neutral
Business Standard - Markets 18h ago
Aurobindo Pharma announces incorporation of subsidiary in Indonesia
The object of incorporation of this wholly owned step down subsidiary is to undertake manufacturing operations in Indonesia.
AUROPHARMAHealthcare
positive
Business Standard - Markets 7d ago
Nifty Pharma rallies 2%; Laurus, Ipca, Aurobindo, Torrent hit record highs
In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.
AONETMMQ50AONETOTALAUROPHARMABANKIETFMOCAPITALPHARMABEESPVTBANIETFFinancial ServicesHealthcare
positive
LiveMint - Markets 9d ago
Aurobindo Pharma’s investors await next leg of growth
Growth would be aided by the Pen-G project ramp-up, Lannett’s integration, new US product launches, expansion in Europe and contribution from higher-margin businesses
AUROPHARMAHealthcare